ArticleJMIR mHealth and uHealth2025
Minimal Clinically Important Difference of Average Daily Steps Measured Through a Consumer Smartwatch in People With Mild-to-Moderate Parkinson Disease: Cross-Sectional Study.
Article in JMIR mHealth and uHealth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Effects of inspiratory muscle training on oxygen consumption, muscle oxygen, and physical activity levels in patients with Parkinson's disease.Scientific reports · 2025Trial
- Real-world gait changes preceding Parkinson's disease diagnosis in a population-scale UK biobank cohort.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- An Information-Driven Approach for the Early Health Technology Sustainability Assessment and the Frugal Design of the Internet of Medical Things: Exploratory Study of Wearable Activity Monitoring Devices.JMIR mHealth and uHealth · 2026Article
- The Influence of Motor and Nonmotor Factors on Ambulatory Activity in People With Parkinson Disease.Journal of neurologic physical therapy : JNPT · 2026Article
- Decreased Physical Activity as an Early Digital Biomarker in Huntington's Disease: A One-Year Observational Study.Brain and behavior · 2026Observational
- Does cognition affect supervised and unsupervised mobility differently in people with Parkinson's disease? A cross-sectional study.Journal of neuroengineering and rehabilitation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies demonstrated the validity, reliability, and accuracy of consumer smartwatches for measuring daily steps in people with Parkinson disease (PD). However, no study to date has estimated the minimal clinically important difference (MCID) for average daily steps (avDS), measured through a consumer smartwatch in people with PD. Objective: This study aimed to calculate the MCID of avDS, measured through a commercial smartwatch (Garmin Vivosmart 4) in people with PD. Methods: People with PD with a disease stage <4, without cognitive impairment, and who were able to walk unaided, wore a Garmin Vivosmart 4 smartwatch for 5 consecutive days on the wrist least affected by the disease, allowing the computation of avDS. To define the 3 levels of MCID for avDS, we used an anchor-based method linked to: (1) scales capturing subtle changes in global mobility and motor functions, (2) clinical and health-related measures, and (3) disease-related patient-reported outcomes. Linear regressions, Student t test, and ANOVA were used to estimate the minimal change in avDS based on anchors relevant change. For each level, the overall MCID was calculated as the average of the variables included, and the range was reported. Results: A total of 100 people with PD were enrolled. Participants took on average 5949 (SD 3034) daily steps, ranging from 357 to 12,620. The MCID of avDS anchored to standardized measures of motor symptoms and mobility was 581 steps/day (range 554-608) or around 10% of mean avDS in our population. The MCID of avDS anchored to clinical and health-related variables was 1200 steps/day (range 350-1683), or around 20% of mean avDS in our population. Finally, the MCID of avDS anchored to disease-related patient-reported outcomes was 1592 steps/day (range 594-2589), or around 27% of the mean avDS in our population. Conclusions: These findings could be relevant for designing future clinical trials involving avDS as a digital mobility outcome in daily life for people with PD and evaluating the effectiveness of the intervention promoting free-living walking in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.